Implication of fibroblast growth factor 7 in ovarian cancer metastases and patient survival
In comparison to ascites, tumors exhibit different transcriptomic profiles that identify candidate biomarkers and drug targets for predicting and preventing recurrence. Among these, elevated tumoral FGF7 validated at the protein level and elevated serum FGF7 were significantly associated with worse patient survival. These results support further development of FGF7 receptor-targeted drugs and serum FGF7 to prevent and predict recurrence, respectively.
Authors
- Zitha Redempta Isingizwe (ORCID: https://orcid.org/0000-0003-1403-0334)
- Justin Garland
- Jacqueline A. Bohn (ORCID: https://orcid.org/0000-0002-7340-6007)
- Brooke Meelheim
- Doris M. Benbrook (ORCID: https://orcid.org/0000-0001-7606-8245)
- Laura F. Mortan (ORCID: https://orcid.org/0000-0002-5305-3486)
Institutions
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-01-16
- DOI
- https://doi.org/10.3389/fonc.2024.1524606
- Citations
- 2
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 1.61
Funders
- National Cancer Institute